WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005038013) ARTISENSE OLIGONUCLEOTIDES OPTIMIZED FOR KIDNEY TARGETING
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/038013    International Application No.:    PCT/US2004/030785
Publication Date: 28.04.2005 International Filing Date: 21.09.2004
IPC:
A61K 31/70 (2006.01), C07H 21/04 (2006.01)
Applicants: ISIS PHARMACEUTICALS, INC. [US/US]; 1896 Rutherford Road, Carlsbad, CA 92008 (US) (For All Designated States Except US).
SIWKOWSKI, Andrew, M. [US/US]; (US) (For US Only).
WANCEWICZ, Edward [US/US]; (US) (For US Only).
LEEDOM, Thomas, A. [US/US]; (US) (For US Only).
WATTS, Lynnetta [US/US]; (US) (For US Only).
GUHA, Mausumee [US/US]; (US) (For US Only).
MONIA, Brett, P. [US/US]; (US) (For US Only)
Inventors: SIWKOWSKI, Andrew, M.; (US).
WANCEWICZ, Edward; (US).
LEEDOM, Thomas, A.; (US).
WATTS, Lynnetta; (US).
GUHA, Mausumee; (US).
MONIA, Brett, P.; (US)
Agent: Paul, K., Legaard; Cozen O'Connor, 1900 Market Street, Philadelphia, PA 19103 (US)
Priority Data:
60/509,450 07.10.2003 US
60/517,334 03.11.2003 US
Title (EN) ARTISENSE OLIGONUCLEOTIDES OPTIMIZED FOR KIDNEY TARGETING
(FR) OLIGONUCLEOTIDES ANTISENS OPTIMISES POUR CIBLER LE REIN
Abstract: front page image
(EN)The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes SGLT2 and connective tissue growth factor (CTGF) in the kidney.
(FR)La présente invention concerne des composés antisens et des procédés de modulation de l'expression de gènes cible exprimés dans le rein. Cette invention concerne en particulier des composés d'oligonucléotides antisens optimisés pour cibler des molécules d'acides nucléiques exprimées dans le rein. Ces composés permettent de moduler efficacement l'expression de gènes cible et de facteurs de croissance de tissu conjonctif CTGF) présents dans le rein.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)